Nisa Investment Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-104
| Closed | -$469 | – | 3101 |
|
|
2025
Q2 | $469 | Sell |
104
-155
| -60% | -$697 | ﹤0.01% | 2885 |
|
|
2025
Q1 | $1.15K | Buy |
259
+205
| +380% | +$1.19K | ﹤0.01% | 2606 |
|
|
2024
Q4 | $423 | Sell |
54
-110
| -67% | -$1.34K | ﹤0.01% | 2861 |
|
|
2024
Q3 | $2.16K | Buy |
164
+111
| +209% | +$1.41K | ﹤0.01% | 2383 |
|
|
2024
Q2 | $640 | Sell |
53
-25
| -32% | -$338 | ﹤0.01% | 2630 |
|
|
2024
Q1 | $1.27K | Buy |
78
+38
| +95% | +$512 | ﹤0.01% | 2322 |
|
|
2023
Q4 | $273 | Hold |
40
| – | – | ﹤0.01% | 2508 |
|
|
2023
Q3 | $218 | Hold |
40
| – | – | ﹤0.01% | 2653 |
|
|
2023
Q2 | $272 | Hold |
40
| – | – | ﹤0.01% | 2672 |
|
|
2023
Q1 | $0 | Sell |
40
-22
| -35% | -$90 | ﹤0.01% | 2738 |
|
|
2022
Q4 | $0 | Sell |
62
-1,677
| -96% | -$12.2K | ﹤0.01% | 2746 |
|
|
2022
Q3 | $7K | Buy |
1,739
+39
| +2% | +$646 | ﹤0.01% | 2254 |
|
|
2022
Q2 | $26K | Hold |
1,700
| – | – | ﹤0.01% | 1972 |
|
|
2022
Q1 | $20K | Buy |
+1,700
| New | +$17.5K | ﹤0.01% | 2055 |
|
|
2021
Q2 | – | Sell |
-1,350
| Closed | -$41 | – | 2394 |
|
|
2021
Q1 | $41 | Hold |
1,350
| – | – | ﹤0.01% | 2024 |
|
|
2020
Q4 | $67K | Buy |
1,350
+200
| +17% | +$9.25K | ﹤0.01% | 1901 |
|
|
2020
Q3 | $44K | Buy |
+1,150
| New | +$45.8K | ﹤0.01% | 1846 |
|
Other funds holding YMAB
Nisa Investment Advisors's YMAB Position: Q3 2025 in Review
Nisa Investment Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 104 shares — an estimated $469 sold.
Nisa Investment Advisors first reported a position in YMAB in Q3 2020 and held it in 17 quarters. The position peaked at $67K in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Nisa Investment Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Nisa Investment Advisors sold 104 Y-mAbs Therapeutics shares in Q3 2025, an estimated $469.
- Nisa Investment Advisors first reported a position in Y-mAbs Therapeutics in Q3 2020 and held it in 17 quarters.
- Nisa Investment Advisors's Y-mAbs Therapeutics position peaked at $67K in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.